MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2967/jnumed.123.265986

Медицинская библиотека · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024

Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy.

Steinhelfer Lisa, Lunger Lukas, Cala Lisena, Pfob Christian H, Lapa Constantin, Hartrampf Philipp E, Buck Andreas K, Schäfer Hannah, Schmaderer Christoph, Tauber Robert, Brosch-Lenz Julia, Haller Bernhard, Meissner Valentin H, Knorr Karina, Weber Wolfgang A, Eiber Matthias

СтатьяПеревод пока не подготовлен

Аннотация

β-emitting 177Lu targeting prostate-specific membrane antigen (PSMA) is an approved treatment option for metastatic castration-resistant prostate cancer. Data on its long-term nephrotoxicity are sparse. This study aimed to retrospectively evaluate post-177Lu-PSMA estimated glomerular filtration rate (eGFR) dynamics for at least 12 mo in a cohort of metastatic castration-resistant prostate cancer patients.

Methods

The institutional databases of 3 German tertiary referral centers identified 106 patients who underwent at least 4 cycles of 177Lu-PSMA and had at least 12 mo of eGFR follow-up data. eGFR (by the Chronic Kidney Disease Epidemiology Collaboration formula) at 3, 6, and 12 mo after 177Lu-PSMA radioligand therapy was estimated using monoexponentially fitted curves through available eGFR data. eGFR changes were grouped (≥15%-<30%, moderate; ≥30%-<40%, severe; and ≥40%, very severe). Associations between eGFR changes (%) and nephrotoxic risk factors, prior treatment lines, and number of 177Lu-PSMA cycles were analyzed using multivariable linear regression.

Results

At least moderate eGFR decreases were present in 45% (48/106) of patients; of those, nearly half (23/48) had a severe or very severe eGFR decrease. A higher number of risk factors at baseline (-4.51, P = 0.03) was associated with a greater eGFR decrease. Limitations of the study were the retrospective design, lack of a control group, and limited number of patients with a follow-up longer than 1 y.

Conclusion

A considerable proportion of patients may experience moderate or severe decreases in eGFR 1 y from initiation of 177Lu-PSMA. A higher number of risk factors at baseline seems to aggravate loss of renal function. Further prospective trials are warranted to estimate the nephrotoxic potential of 177Lu-PSMA.

Для цитирования: Steinhelfer Lisa, Lunger Lukas, Cala Lisena, Pfob Christian H, Lapa Constantin, Hartrampf Philipp E, Buck Andreas K, Schäfer Hannah, Schmaderer Christoph, Tauber Robert, Brosch-Lenz Julia, Haller Bernhard, Meissner Valentin H, Knorr Karina, Weber Wolfgang A, Eiber Matthias. Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2024. DOI: 10.2967/jnumed.123.265986.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.